Table 1.
Demographic and clinical characteristics of Parkinson’s disease (PD) and control groups.
| PD groups | Control group | ||
|---|---|---|---|
| Cognitive decline | Cognitive stable | ||
| Age (years) | 62.97 ± 9.84 | 62.05 ± 10.03 | 63.10 ± 10.26 |
| Sex | 22M/15F | 17M/5F | 17M/4F |
| Initial Montreal Cognitive Assessment (MoCA) score | 27.00 ± 3.57 | 26.73 ± 3.49 | 27.76 ± 1.48 |
| Final Montreal Cognitive Assessment (MoCA) score | 24.68 ± 4.51 | 26.73 ± 3.49 | |
| ∆MoCA score | −2.32 ± 2.06 | 0.00 ± 0.00 | |
| Months between MoCA evaluations | 57.65 ± 15.14 | 57.55 ± 18.94 | |
| Months between scan & MoCAinitial | 0.541 ± 1.99 | 0.318 ± 0.72 | |
| Months between PD symptom onset & MoCAinitial | 41.41 ± 40.26 | 38.41 ± 27.84 | |
| Months between scan & PD symptom onset | 41.14 ±4 0.10 | 38.68 ± 28.02 | |
| Months between scan & formal PD diagnosis | 19.24 ± 34.50 | 17.23 ± 26.61 | |
| Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)-III | 22.62 ± 11.78 | 20.82 ± 11.31 | |
| Affected side (left/right/asymmetric) | 16/20/1 | 5/17/0 | |
| Hoehn & Yahr stage (1/2/3/4/5) | 9/27/1/0/0 | 8/14/0/0/0 | |
| Education (years) | 15.32 ± 2.59 | 15.55 ± 3.07 | |